## Matrix metalloproteinase inhibitor, doxycycline and progression of calcific aortic valve disease in hyperlipidemic mice

Jae-Joon Jung, PhD<sup>1,2\*</sup>, Mahmoud Razavian, PhD<sup>1,2\*</sup>, Hye-Yeong Kim<sup>1,2</sup>, PhD, Yunpeng Ye, PhD<sup>1,2</sup>, Reza Golestani, MD, PhD<sup>1,2</sup>, Jakub Toczek, PhD<sup>1,2</sup>, Jiasheng Zhang, MD<sup>1,2</sup>, Mehran M. Sadeghi, MD<sup>1,2</sup>

<sup>1</sup> Section of Cardiovascular Medicine and Cardiovascular Research Center, Yale University School of Medicine, New Haven, CT, United States. <sup>2</sup> VA Connecticut Healthcare System, West Haven, CT, United States.

## **Supplemental Figure**

Doxycycline and aortic valve MMP expression in CAVD. GAPDH-normalized MMP-9 (A) and MMP-12 (B) expression assessed by quantitative RT-PCR in aortic valve tissues of control and doxycycline-treated mice on high fat diet. n = 4 in each group.

